Relx (LON:REL) Given Hold Rating at Deutsche Bank

Share on StockTwits

Relx (LON:REL)‘s stock had its “hold” rating restated by Deutsche Bank in a research note issued to investors on Friday, ThisIsMoney.Co.Uk reports.

Other equities analysts have also issued reports about the company. Goldman Sachs Group upgraded Las Vegas Sands to a “buy” rating in a research report on Tuesday, June 11th. UBS Group set a $54.00 price target on Westlake Chemical and gave the stock a “sell” rating in a research report on Tuesday, July 2nd. Finally, JPMorgan Chase & Co. set a $195.00 price target on bluebird bio and gave the stock a “buy” rating in a research report on Friday, May 17th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of GBX 1,821.50 ($23.80).

REL opened at GBX 1,939.50 ($25.34) on Friday. The stock’s 50 day moving average is GBX 1,898.85. The company has a current ratio of 0.44, a quick ratio of 0.36 and a debt-to-equity ratio of 270.50. Relx has a 1 year low of GBX 1,466.50 ($19.16) and a 1 year high of GBX 1,982.50 ($25.90). The company has a market cap of $37.78 billion and a price-to-earnings ratio of 27.16.

In other news, insider Henry Udow sold 50,831 shares of Relx stock in a transaction that occurred on Monday, April 29th. The stock was sold at an average price of GBX 1,759 ($22.98), for a total value of £894,117.29 ($1,168,322.61).

Relx Company Profile

RELX PLC provides information based-analytics and decision tools for professional and business customers in the United States and internationally. It operates through four segments: Scientific, Technical & Medical; Risk & Business Analytics; and Exhibitions. The Scientific, Technical & Medical segment provides information and analytics to institutions and professionals that enables progress in science, advance healthcare, and performance improvement.

Featured Story: Golden Cross

Analyst Recommendations for Relx (LON:REL)

Receive News & Ratings for Relx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relx and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Spire Healthcare Group  Receives Hold Rating from Liberum Capital
Spire Healthcare Group Receives Hold Rating from Liberum Capital
Deutsche Bank Reaffirms “Hold” Rating for Sophos Group
Deutsche Bank Reaffirms “Hold” Rating for Sophos Group
Sophos Group’s  “Hold” Rating Reiterated at Liberum Capital
Sophos Group’s “Hold” Rating Reiterated at Liberum Capital
Deutsche Bank Reaffirms Hold Rating for Standard Life Aberdeen
Deutsche Bank Reaffirms Hold Rating for Standard Life Aberdeen
SEGRO’s  “Buy” Rating Reiterated at Deutsche Bank
SEGRO’s “Buy” Rating Reiterated at Deutsche Bank
The Sage Group  Stock Rating Reaffirmed by Deutsche Bank
The Sage Group Stock Rating Reaffirmed by Deutsche Bank


© 2006-2019 Ticker Report